Renin-Inhibitors Market (Updated Version Available)

The report offers detailed coverage of Renin-Inhibitors industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Renin-Inhibitors by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
Renin inhibitors are one of four classes of compounds that affect the renin-angiotensin-aldosterone system. Renin inhibitors produce vasodilation by inhibiting the activity of renin, which is responsible for stimulating angiotensin II formation. Renin is a proteolytic enzyme that is released by the kidneys in response to sympathetic activation, hypotension, and decreased sodium delivery to the distal renal tubule. Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.
USA is still the largest consumption region of Tekturna, occupied about 56% market share globally, with revenue 39.21 million USD in 2017. At the same time, Asia will see the considerable growth since Noden Pharma DAC had successfully entered into an agreement with Orphan Pacific (Japan) and Lee\'s Pharmaceutical Holdings Limited (China).

The report forecast global Renin-Inhibitors market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021-2025.

First, this report covers the present status and the future prospects of the global Renin-Inhibitors market for 2015-2025.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].

Key Companies
Novartis
Noden Pharma

At the same time, we classify Renin-Inhibitors according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.

Market Segment as follows:
Market by Order Type
150mg/Tablet
300mg/Tablet
Market by Application
Age below 45
Age 45-55
Age 55-65
Age above 65

By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]

The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Renin-Inhibitors market for the forecast period 2021 - 2025?
• What are the driving forces in the Renin-Inhibitors market for the forecast period 2021 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Renin-Inhibitors industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?